Cordyceps sinensis (Cs) (DongChongXiaCao in Chinese), is a rare and precious Chinese herb facing a stringent shortage of natural supply (i.e., overharvesting and continued destruction of habitat) due to increasing world demand. Th is increasing shortage in supply has driven the price of wild collected Cordyceps up to previously unimaginable levels, making wild collected C. sinensis the most costly medicinal raw material available today. Th e cultivated mycelium of the C. sinensis fungi has been shown to signifi cantly lower the cost and has proven to be a feasible alternative to the natural species for herbal medicine, pharmaceutical, and functional food use. Since the mid-1980s there have been a number of diff erent anamorphs of C. sinensis isolated and brought into cultivation. While these modern biotechnologically cultivated anamorphs appear to hold great potential for relieving the worldwide shortage of this valuable medicine, the sheer number of diff erent anamorphs and their widely diff ering chemical and cultivation parameters pose many questions about the eff ectiveness and equivalence to the wild collected C. sinensis.
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Cordyceps sinensis (Cs) (DongChongXiaCao in Chinese), is a rare and precious Chinese herb facing a stringent shortage of natural supply (i.e., overharvesting and continued destruction of habitat) due to increasing world demand. Th is increasing shortage in supply has driven the price of wild collected Cordyceps up to previously unimaginable levels, making wild collected C. sinensis the most costly medicinal raw material available today. Th e cultivated mycelium of the C. sinensis fungi has been shown to signifi cantly lower the cost and has proven to be a feasible alternative to the natural species for herbal medicine, pharmaceutical, and functional food use. Since the mid-1980s there have been a number of diff erent anamorphs of C. sinensis isolated and brought into cultivation. While these modern biotechnologically cultivated anamorphs appear to hold great potential for relieving the worldwide shortage of this valuable medicine, the sheer number of diff erent anamorphs and their widely diff ering chemical and cultivation parameters pose many questions about the eff ectiveness and equivalence to the wild collected C. sinensis.
In this work, we investigated and elucidated a fungus species, which was isolated from the wild Cs herb, which we have identifi ed as a new anamorph of Cs. Its UV, IR, and HPLC spectra all exhibit high similarity in chemical composition to those of natural Cs herbs. As in the case of the wild fungus, this fungus (extracted by water or ethanol) exhibits strong antioxidant properties, scavenging free radicals (as shown by DPPH assay), and inhibits lipid peroxidation (shown by TBA assay). It also shows strong antitumor activity in a number of diff erent tumor cell lines, both in vitro and in vivo, and shows potent inhibition of tumor growth in the Murine model.
Th ese results suggest that this newly isolated Cs anamorph more closely mirrors the chemical composition and pharmacological activity of the natural Cs than has any previously identifi ed anamorph, indicating the potential for an improvement upon the existing fungal lines in Cordyceps cultivation. Th e morphological characteristics, genetic identifi cation, biotechnological potential, and detailed growth parameters in both liquid cultivation and solid state fermentation for this fungal mycelium are fully evaluated and indicate this new anamorph as having great potential as an eff ective and low-cost substitute for the natural Cs herb.
